Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 29, 2024 07:30 ET | Source: Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results

– Reports YCANTH™ revenue of $1.9M for fourth quarter and $4.7M for full year 2023 – – Over 200 million lives now covered on commercial insurance and managed Medicaid plans – – Conference Call...
February 27, 2024 07:30 ET | Source: Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Announces Participation in the TD Cowen 44th Annual Healthcare Conference

WEST CHESTER, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin...
February 22, 2024 07:30 ET | Source: Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024

WEST CHESTER, Pa., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin...
February 05, 2024 07:30 ET | Source: Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Files Lawsuit Against Canadian Drug Manufacturer for False Advertising and Unfair Competition

Lawsuit alleges false and misleading advertising and promotion of unapproved cantharidin-containing drugs by Dormer Laboratories in violation of federal and state law WEST CHESTER, Pa., Feb. 05,...
January 29, 2024 07:30 ET | Source: Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Receives Permanent J-Code (J7354) for YCANTH™ from Centers for Medicare and Medicaid Services

WEST CHESTER, Pa., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin...
January 05, 2024 07:30 ET | Source: Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Announces Last Patient Dosed in Part 2 of Phase 2 Study of VP-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma

There are approximately 3-4 million diagnoses of basal cell carcinomas in the U.S. each year, with a high unmet need for new treatment options Company reiterates lesion clearance data from Part 2...
January 04, 2024 07:30 ET | Source: Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Announces Receipt of Minutes from Type C Meeting with FDA Regarding Clinical Development of YCANTH™ for the Treatment of Common Warts

WEST CHESTER, Pa., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin...
January 03, 2024 07:30 ET | Source: Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Announces Specialty Pharmacy Partnership Agreement with Walgreens to Distribute YCANTH™

WEST CHESTER, Pa., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin...
December 15, 2023 06:00 ET | Source: Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals’ Development and Commercialization Partner, Torii Pharmaceutical Co., Ltd., Announces Positive Top-line Results from a Confirmatory Phase 3 Trial of TO-208 for the Treatment of Molluscum Contagiosum in Japan

WEST CHESTER, Pa., Dec. 15, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin...
November 10, 2023 08:00 ET | Source: Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Announces Presentation at the Jefferies Global Healthcare Conference in London

WEST CHESTER, Pa., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin...